Table 3. Univariate and multivariate Cox survival analysis in patients with BCLC stage 0 and stage A hepatocellular carcinoma.
| n = 1,001 | Crude Hazard Ratio | Adjusted Hazard Ratio | ||
|---|---|---|---|---|
| HR (95% CI) | P value | HR (95% CI) | P value | |
| Diabetes mellitus (no/yes) | 1.61 (1.23–2.12) | 0.001 | 1.45 (1.08–1.93) | 0.013 |
| Age (per 10 years increment) | 1.24 (1.11–1.38) | <0.001 | 1.11 (0.98–1.26) | 0.089 |
| Male gender (female/male) | 1.02 (0.77–1.43) | 0.902 | - | - |
| Hepatitis B (negative/positive) | 0.66 (0.52–0.85) | 0.001 | 0.73 (0.52–1.01) | 0.054 |
| Hepatitis C (negative/positive) | 1.37 (1.07–1.76) | 0.012 | 0.87 (0.63–1.22) | 0.424 |
| Alcoholism (no/yes) | 1.21 (0.84–1.74) | 0.309 | - | - |
| Albumin (per 1 g/dl decrement) | 2.33 (1.85–2.94) | <0.001 | 1.82 (1.37–2.38) | <0.001 |
| Bilirubin (per 1 mg/dl increment) | 1.51 (1.29–1.76) | <0.001 | 1.27 (1.07–1.52) | 0.008 |
| INR (per 1.0 increment) | 3.58 (1.61–7.97) | 0.002 | 1.37 (0.43–4.30) | 0.593 |
| Sodium (per 1 mEq/l increment) | 1.03 (0.99–1.07) | 0.210 | - | - |
| AFP (per 10,000 ng/ml increment) | 1.30 (1.17–1.44) | <0.001 | 1.34 (1.20–1.48) | <0.001 |
| eGFR (per 10 mL/min/1.73 m2 decrement) | 1.12 (1.06–1.19) | <0.001 | 1.11 (1.04–1.19) | 0.001 |
| Variceal bleeding (no/yes) | 1.39 (0.44–4.33) | 0.574 | - | - |
| Total tumor volume (per 1,000 ml increment) | 1.05 (0.96–1.14) | 0.274 | - | - |
| Vascular invasion (no/yes) | - | - | - | - |
| Ascites (no/yes) | 1.55 (0.90–2.65) | 0.114 | - | - |
| Platelet count (per 10,000 mm3 decrement) | 1.05 (1.03–1.08) | <0.001 | 1.03 (1.0–1.05) | 0.029 |
Factors with P value < 0.1 in the univariate analysis were introduced into the Cox multivariate survival analysis.
The forepart of the parentheses was set as the reference group in univariate and multivariate analysis.
AFP, alpha-fetoprotein; CI, confidence interval; eGFR, estimated glomerular filtration rate; HR, hazard ratio; INR, international normalized ratio